$4.01
0.50% yesterday
Nasdaq, Jul 11, 10:13 pm CET
ISIN
US03843E1047
Symbol
AQST
Sector
Industry

Aquestive Therapeutics, Inc. Stock price

$4.01
+0.60 17.60% 1M
+0.90 28.94% 6M
+0.45 12.64% YTD
+1.28 46.89% 1Y
+3.19 389.02% 3Y
-0.20 4.75% 5Y
-12.04 75.02% 10Y
-12.04 75.02% 20Y
Nasdaq, Closing price Fri, Jul 11 2025
-0.02 0.50%
ISIN
US03843E1047
Symbol
AQST
Sector
Industry

Key metrics

Basic
Market capitalization
$398.3m
Enterprise Value
$363.4m
Net debt
positive
Cash
$68.7m
Shares outstanding
99.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
7.3 | 8.7
EV/Sales
6.7 | 7.9
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-59.3%
Return on Equity
73.4%
ROCE
-49.1%
ROIC
-214.9%
Debt/Equity
-0.6
Financials (TTM | estimate)
Revenue
$54.2m | $46.0m
EBITDA
$-40.5m | $-50.1m
EBIT
$-41.2m | $-59.4m
Net Income
$-54.2m | $-73.3m
Free Cash Flow
$-49.0m
Growth (TTM | estimate)
Revenue
5.3% | -20.2%
EBITDA
-122.2% | -66.8%
EBIT
-111.6% | -93.0%
Net Income
-88.5% | -66.0%
Free Cash Flow
-84.3%
Margin (TTM | estimate)
Gross
68.4%
EBITDA
-74.7% | -109.1%
EBIT
-75.9%
Net
-100.0% | -159.4%
Free Cash Flow
-90.4%
More
EPS
$-0.6
FCF per Share
$-0.5
Short interest
14.3%
Employees
142
Rev per Employee
$410.0k
Show more

Is Aquestive Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Aquestive Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Aquestive Therapeutics, Inc. forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a Aquestive Therapeutics, Inc. forecast:

Buy
93%
Hold
7%

Financial data from Aquestive Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
54 54
5% 5%
100%
- Direct Costs 17 17
16% 16%
32%
37 37
20% 20%
68%
- Selling and Administrative Expenses 59 59
67% 67%
108%
- Research and Development Expense 20 20
27% 27%
36%
-41 -41
122% 122%
-75%
- Depreciation and Amortization 0.65 0.65
47% 47%
1%
EBIT (Operating Income) EBIT -41 -41
112% 112%
-76%
Net Profit -54 -54
89% 89%
-100%

In millions USD.

Don't miss a Thing! We will send you all news about Aquestive Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aquestive Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
5 days ago
WARREN, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the Aquestive management team will participate in the Leerink Partners Therapeutics Forum: I&I and Meta...
Positive
Seeking Alpha
17 days ago
Anaphylm's FDA approval process is a major catalyst, with a PDUFA date set for January 31, 2026, and potential AdCom or partnership news ahead. Anaphylm offers a needle-free, orally delivered epinephrine alternative, boasting rapid absorption and strong clinical data, supporting high approval confidence. If approved, Anaphylm could drive significant revenue growth and a potential company rerati...
Neutral
GlobeNewsWire
17 days ago
WARREN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that two poster presentations highlighting results from the investigational use of Anaphylm™ (epinephrine) ...
More Aquestive Therapeutics, Inc. News

Company Profile

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.

Head office United States
CEO Daniel Barber
Employees 142
Founded 2004
Website aquestive.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today